In the Russian Federation, Pfizer Inc. 15.03.2017 the preparation of Vindakel is registered (tafamidis). Earlier it was approved by the European Union and the FDA.
The full official instruction of the state register of medicines totrade medication Windouchel read in the medicinal guide TALKDRUGS here.
Windakel used in treatment Transthyretin family amyloid polyneuropathy. Tafamidis blocks the accumulation of transthyretin, which blocks the work of nerve fibers, including breaking their integrity, which leads to the development of severe polyneuropathy. Shown to adults with symptomatic polyneuropathy, stage 1.
The drug is available in capsules containing 20 mg of active ingredient tafamidis. Windakel take once a day, the treatment continues as long as the clinical effect remains.
To date, this is the only drug for the treatment of amyloid diseases, the effectiveness of which is confirmed by clinical trials: the main clinical study (Fx-005) and an open 12-month extended trial (Fx-006), in which long-term safety and efficacy of the drug were evaluated Windakel in patients with familial amyloid polyneuropathy. According to the results tafamidis effectively slowed down (by 51-81%) development of peripheral neurologic disorders, compared with the placebo group.
Adverse reactions when taking the drug: diarrhea, upper abdominal pain, urinary tract infections, vaginal infections.
Dr. Teresa Coelho, Santo Antonio Hospital, Porto, Portugal, who participated in clinical trials, believes that "Windakel offers new hope to patients diagnosed with familial amyloid polyneuropathy. "